...Hidefumi Kasuga; Yuki Kataoka; Fuyuki Yamamoto; Takashi Mizutani; Shingo Tsuji; Sakiho Tanaka; Shinji Mizuarai Background: Common mutations (exon 19 deletion; ex19del or L858R point mutation; L858R) of the epidermal growth factor receptor (EGFR) are found in patients with non-small cell lung cancer...

... with uncommon EGFR mutations (uEGFR), such as G719X, S768I, L861Q and exon 20 insertions, first-generation TKIs might still be one of the mainstay choices in clinic. However, they exhibited heterogeneity in treatment responses. Here, we aimed to elucidate different genomic profiles of tumors carrying uncommon...

...Shansong Zheng; Wei Deng; Qingmei Zheng; Yingying Yang; Na Li; Tan Pang; Xueying Feng; Simon Taylor; Lina Ma; Yaqiong Wu; Ziwei Zhao Background: The 3^rd-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), like osimertinib, provide marked clinical benefit...

...Yan Yang; Monique Nilsson; Sonia Patel; Jacqulyne Robichaux; Alissa Poteete; Xiaoxing Yu; Fahao Zhang; Simon Heeke; Yu Qian; Junqin He; John Heymach The leading cause of cancer-related deaths in the US is non-small cell lung cancer (NSCLC), and about 10-15% of NSCLC cases harbor EGFR activating...

...Anthony El-Khoueiry; Juanita Lopez; Omar Saavedra; Mark Awad; Jacob Thomas; Crescens Tiu; Elena Garralda; Bettina Rehbein; Gabriele Hintzen; Kerstin Pietzko; Christa Raab; Erich Rajkovic; Paulien Ravenstijn; Michael Emig AFM24 is a first-in-class, tetravalent, bispecific ICE® that binds to EGFR...

...Lu Yang; Arup Bhattacharya; Yun Li; Sandra Sexton; Xiang Ling; Fengzhi Li; Yuesheng Zhang Background & Goals: Epidermal growth factor receptor (EGFR), an oncogenic receptor tyrosine kinase, is a major therapeutic target in several types of cancers. Several EGFR inhibitors are used to treat EGFR...

..., and temozolomide has been unsuccessful in meaningfully extending survival and preventing recurrence; thus, novel therapeutics are urgently needed. One proposed targeted treatment strategy for GBM involves using small molecule inhibitors against common genetic mutations. Epidermal growth factor receptor (EGFR...

...David J. de Gorter; Marie O'Connor; Alexandre Deshiere; Martijn van Rosmalen; Szabolcs Fatrai; Jeroen Lammerts van Bueren; Cecile A. Geuijen Introduction: MCLA-129 is an ADCC-enhanced IgG1 bispecific antibody that targets epidermal growth factor receptor (EGFR) and c-MET. The HGF/c-MET pathway...

... cell lung cancer (NSCLC), which makes up ~85% of lung cancer cases, is mainly treated with radiotherapy, chemotherapies, and targeted agents. Epidermal growth factor receptor (EGFR) is commonly mutated in NSCLC patients and leads to increased proliferation and cell survival. The standard-of-care...

...Brion W. Murray; Anjali Pandey; Bruce Roth; Tracy Saxton; Daniel J. Estes; Himanshu Agrawal; Santosh Vishwakarma; Gurulingappa Hallur; Ishtiyaque Ahmad; Ravi Trivedi; Helen Jenkins; Paul G. Pearson Exon 20 insertion mutations (Ex20ins) are the third most common type of EGFR oncogenic mutation...

...Wei-Sheng Huang; Sara Nadworny; Narayana Narasimhan; Charles J. Eyermann; David C. Dalgarno; Victor M. Rivera; William C. Shakespeare Introduction: EGFR activating mutations are observed in 10-50% of NSCLC patients and the common mutations (L858R [L] and exon 19 deletions [D]) are initially...

...; John D. Minna; John V. Heymach Approximately 15% of all patients with non-small cell lung cancer (NSCLC) and nearly 35% of Asian patients with NSCLC harbor activating mutations within the epidermal growth factor receptor (EGFR). Although these patients are initially highly sensitive to first or second...

...Youngjoo Lee; Yu-Ra Choi; Eun Hye Kang; Sunshin Kim; SeogYun Park; Ji-Youn Han Background: In recent clinical trials for EGFR-mutant lung cancer acquiring MET amplification as resistance to EGFR inhibitor, two-drug combination treatment showed promising anti-tumor activity. However...

... that pharmacological inhibition of a glutaminolytic enzyme glutamate dehydrogenase 1 (GDH1) and ribosomal S6 kinase 2 (RSK2) synergistically attenuates cell invasion, anoikis resistance, and immune escape more evidently in tumors harboring EGFR activating or EGFR inhibitor-resistant mutations. Mechanistically, GDH1...

...Qinglin Du; Wengang Zeng; Xueyan Yang; Liwen Liang; Xueqin Li; Yan Li; Yiqi Cao; Zongjun Xia; Jing Zhang; Qian Ding; Shuhua Han Background: The EGFR tyrosine kinase inhibitors (TKIs) have been effectively used for non-small cell lung cancer (NSCLC) driven by EGFR mutations. However, patients...

... factor receptor (EGFR) is frequently mutated in NSCLC. A handful of anti-EGFR Tyrosine Kinase Inhibitor therapies are approved by the FDA; however, most patients develop resistance over time to these treatments. Both monitoring primary EGFR mutations to predict treatment response and precociously...

...Yi-Long Wu; Ji-Youn Han; Terufumi Kato; Fabrice Barlesi; Edward B. Garon; Federico Cappuzzo; Yuji Shibata; Nathalie Smith; Sadhvi Khanna; Riccardo Belli; Alejandro Yovine; Daniel Tan Background: MET amplification can arise as a bypass resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs...

...Mackenzie L. Hagan; Michael McGrath; Carol Joseph; Allison Lewis; John R. Barrett; Muthusamy Thangaraju; David Gewirtz; Patricia V. Schoenlein EGFR is upregulated commonly in multiple cancer types, including breast cancer. However, the multiple role(s) of EGFR in breast cancer are not fully...

...Jinah Kim; Horyun Choi; Yeun Ho Lee; Leeseul Kim; Young Kwang Chae Amivantamab is a bispecific antibody against EGF and MET receptors, approved for patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion after disease has progressed on or after platinum-based...

...J. Nicholas Bodor; Joanne Xiu; Vinicius Ernani; Supreet Kaur; Hirva Mamdani; Pavel Brodskiy; Sai-Hong I. Ou; Patrick C. Ma; Margie L. Clapper; W. Michael Korn; Joseph Treat Background: While most EGFR-mutant NSCLC tumors are resistant to checkpoint inhibitors, a small subset has durable responses...